No studies have been performed regarding the carcinogenic potential and/or effect on fertility of MxP. It has been observed that the administration of MxP in a dose > 3 times the recommended can produce the degeneration of heart tissue and a dose > 10 times the recommended there are reports of gliosis, axonal degeneration in the spinal cord and body tremors.FDA label
CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the Pseudomonas exotoxin A (PE38) which does not have the cell-binding portion.A38864
MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.A38864 It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.L4568
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Moxetumomab pasudotox. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Moxetumomab pasudotox. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Moxetumomab pasudotox. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Moxetumomab pasudotox. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Quinisocaine. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Moxetumomab pasudotox is combined with Etrasimod. |